Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993)

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1137-1146

  Reid, Joel M ^a   Buhrow, Sarah A ^a   Gilbert, Judith A ^a   Jia, Lee ^b   Shoji, Mamoru ^c   Snyder, James P ^d   Ames, Matthew M ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Curcumin; EF 24; LC MS MS; Mouse; Pharmacokinetics

Indexed keywords

3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; ALBUMIN; CURCUMIN; FORMIC ACID; METHANOL; NSC 716993; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ELECTROSPRAY; ELUTION; HUMAN; HUMAN CELL; HYDROXYLATION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRECIPITATION; PRIORITY JOURNAL; REDUCTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CHROMATOGRAPHY, LIQUID; CURCUMIN; DOGS; HUMANS; MALE; MASS SPECTROMETRY; MICE; PIPERIDONES; PROTEIN BINDING; RATS;

EID: 84903788053     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2447-3     Document Type: Article

References (30)

1. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and antiangiogenesis agents. Bioorg Med Chem 12:3871-3883 (Pubitemid 38798249)
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807-818
3. Mosley CA, Liotta DC, Snyder JP (2007) Highly active anticancer curcumin analogues. Adv Exp Med Biol 595:77-103
4. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, Sun A, Snyder JP, Liotta DC, Jones DP, Shoji M (2005) EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16:263-275 (Pubitemid 40283941)
5. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP, Liotta D, Fu H (2008) Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 74:654-661
6. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282:28609-28618 (Pubitemid 47606012)
7. Subramaniam D, May R, Sureban SM, Lee KB, George R, Kuppusamy P, Ramanujam RP, Hideg K, Dieckgraefe BK, Houchen CW, Anant S (2008) Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 68:1962-1969 (Pubitemid 351416583)
8. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P (2008) EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7:2409-2417
9. Shu HG, Brown A, Yoon Y, Gao H, Purcell J, Snyder JP, Liotta DC, Shim H (2008) Radiosensitization of glioma cells with the curcumin analogs EF24 and UBS109. Abstract, ACR 99th annual meeting
10. Landais I, Hiddingh S, McCarroll M, Yang C, Sun A, Turker MS, Snyder JP, Hoatlin ME (2009) Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol Cancer 8:133
11. Kachnic LA, Li L, Fournier L, Willers H (2010) Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 292:73-79
12. Thomas SL, Zhao J, Li Z, Lou B, Du Y, Purcell J, Snyder JP, Khuri FR, Liotta D, Fu H (2010) Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol 80:1309-1316
13. Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker ET, Pohl J, Mosley CA, Alizadeh AR, Liotta DC, Snyder JP (2008) Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target 16:185-197 (Pubitemid 351460647)
14. Sun A, Shoji M, Lu YJ, Liotta DC, Snyder JP (2006) Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 49:3153-3158 (Pubitemid 43830514)
15. Sun A, Lu YJ, Hu H, Shoji M, Liotta DC, Snyder JP (2009) Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett 19:6627-6631
16. Buhrow SA, Reid JM, Jia L, Shoji M, Snyder JP, Liotta DC, Ames MM (2005) LC/MS/MS assay and mouse pharmacokinetics and metabolism of the novel curcumin analog EF-24 (NSC 716993). Proc Am Assoc Cancer Res 46: Abstract #4169
17. Ernster L, Siekevitz P, Palade GE (1962) Enzyme-structure relationships in the endoplasmic reticulum of rat liver. J Cell Biol 15:541-562
18. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035 (Pubitemid 24258105)
19. Hanson KL, Vanden Brink BM, Babu KN, Allen KE, Nelson WL, Kunze KL (2010) Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 38:963-972
20. Venkatesh G, Ramanathan S, Nair NK, Mansor SM, Sattar MA, Khan MA, Navaratnam V (2007) Permeability of atenolol and propranolol in the presence of dimethyl sulfoxide in rat singlepass intestinal perfusion assay with liquid chromatography/UV detection. Biomed Chromatogr 21:484-490 (Pubitemid 46736182)
21. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61:1058-1064 (Pubitemid 32174425)
22. Pan MH, Huang TM, Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27:486-494
23. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900 (Pubitemid 32994823)
24. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854 (Pubitemid 39383033)
25. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17:1411-1417
26. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11:105-111 (Pubitemid 34118319)
27. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90:1011-1015 (Pubitemid 38499692)
28. Olivera A, Moore TW, Sun A, Liotta DC, Snyder JP, Shim H, Marcus AL, Miller AH, Pace TW (2010) Inhibition of the NF-kB signaling pathway by the curcumin analog, 3,5-bis(2-pyridinylmethylidene)-4piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol 12:368-377
29. Zhu S, Moore TW, Lin X, Morii N, Mancini A, Howard RB, Culver D, Arrendale RF, Reddy P, Evers TJ, Zhang H, Sica G, Chen ZG, Sun A, Fu H, Khuri FR, Shin DM, Snyder JP, Shoji M (2012) Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol 4:633-640
30. Yamaguchi M, Moore TW, Sun A, Snyder JP, Shoji M (2012) Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-kappaB inhibition. Integr Biol 4:905-913